Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Bucharest – page 35

660 clinical trials in Bucharest, Romania across 19 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Bucharest at a glance
660
clinical trials
  • Research sites19
Type of trial
Recruitment status
Quick filters

660 trials in Bucharest

Open in trial search

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cobolimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Evaluation of Long-term Safety and Efficacy of Enpatoran in Subacute Cutaneous, Discoid, and Systemic Lupus Erythematosus Post-WILLOW Study Completion

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran
  • Sponsor:Merck Healthcare KGaA

HIV infection

Not recruiting

Safety, Tolerability and Antiretroviral Activity of a Single Oral Dose of MK-8527 in ART‑Naïve Adults with HIV‑1

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:MK-8527
  • Sponsor:Merck Sharp & Dohme LLC

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Study of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Novartis Pharma AG

Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Breast cancer+3

Not recruiting

Study of romiplostim for treating low platelet counts caused by chemotherapy in adults with non-small cell lung cancer, ovarian cancer, or breast cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Romiplostim
  • Sponsor:Amgen Inc.
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Dermatomyositis

Not recruiting

A study testing brepocitinib compared to placebo for adults with dermatomyositis to see if it works and is safe

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Brepocitinib Tosilate
  • Sponsor:Priovant Therapeutics Inc.

Psoriasis

Not recruiting

Testing IDOR-1117-2520 for Adults with Moderate to Severe Chronic Plaque Psoriasis With or Without Psoriatic Arthritis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:IDOR-1117-2520C
  • Sponsor:Idorsia Pharmaceuticals Ltd.

Other cities in Romania

The busiest research cities in the country

All 65 cities in Romania

Clinical research in Bucharest

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical trial activity in Bucuresti includes a strong focus on cardiovascular diseases, with studies targeting atherosclerotic risk and event prevention in high-risk patients.

  • Atherosclerotic cardiovascular disease
  • Primary prevention of ASCVD
  • Risk reduction for major cardiovascular events

These trials are mainly designed to evaluate new approaches that may lower the chance of heart attacks, strokes, and other serious vascular complications.

02 Nervous System Diseases

The nervous system diseases portfolio covers conditions affecting cognition, movement, and headache disorders, reflecting a broad interest in neurological care and symptom control.

  • Agitation associated with Alzheimer’s disease
  • Migraine
  • Episodic migraine

Research here is focused on testing treatments that may improve daily functioning, reduce symptoms, and support long-term management in both adults and pediatric patients.

03 Mental Disorders

Trials in mental disorders are examining new options for people living with schizophrenia, especially those who do not respond well to standard antipsychotic treatment.

  • Schizophrenia
  • Adjunctive symptom management
  • Treatment response in difficult-to-manage psychiatric illness

The overall aim is to better control symptoms and improve treatment effectiveness for patients with ongoing psychiatric needs.

04 Respiratory Tract Diseases

In the area of respiratory tract diseases, studies are centered on moderate-to-severe uncontrolled asthma, with attention on therapies that may offer better symptom control.

  • Moderate-to-severe uncontrolled asthma
  • Symptom relief and disease control
  • Safety and effectiveness of new asthma treatments

These trials are exploring whether investigational therapies can help patients breathe more easily and reduce the burden of persistent asthma.

05 Nutritional and Metabolic Diseases

Research in nutritional and metabolic diseases includes studies on obesity and overweight, as well as related joint problems that often accompany excess body weight.

  • Obesity
  • Overweight
  • Knee osteoarthritis

The goal is to assess therapies that may support weight management and improve associated health outcomes, including joint pain and mobility.

06 Neoplasms

Oncology research in Bucuresti includes trials for limited-stage small cell lung cancer after chemoradiotherapy, with a focus on consolidation treatment strategies.

  • Limited-stage small cell lung cancer
  • Post-chemoradiotherapy disease control
  • Treatment effectiveness in lung cancer

These studies are evaluating whether new immunotherapy combinations can help maintain remission and improve survival outcomes.

07 Neurodegenerative and Psychiatric Symptom Research

Some trials bring together neurology and psychiatry by studying agitation in Alzheimer’s disease, an important symptom that can affect patients and caregivers alike.

  • Agitation associated with Alzheimer’s disease
  • Behavioral symptom management
  • Long-term safety and tolerability

The research is intended to find better ways to manage distressing behavioral symptoms while supporting longer-term treatment use.

08 Inflammation and Renal-Related Research

Another active area involves patients with ESKD undergoing dialysis, where studies are exploring inflammatory markers linked to cardiovascular risk.

  • End-stage kidney disease
  • Dialysis-associated inflammation
  • Reduction of high-sensitivity C-reactive protein

These trials aim to better understand whether new therapies can help reduce inflammation and potentially improve overall health outcomes in this high-risk group.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.